Pharmaceutical Preparations · CIK 1599298
Summit Therapeutics develops and commercializes novel oncology medicines, including ivonescimab, to treat serious unmet medical needs
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article · skews ▼ negative.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Oct 21, 2025: 3 insiders bought $11.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 21, 2025 | Xia YuDirector | Buy | 533,617 | $18.74 | $10.0M |
| Oct 21, 2025 | Duggan Robert WCo-Chief Executive Officer | Buy | 26,680 | $18.74 | $500K |
| Oct 21, 2025 | Zanganeh MahkamCo-Chief Executive Officer | Buy | 26,680 | $18.74 | $500K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.